NASDAQ$ARVN
Arvinas Inc. · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Arvinas reported its first quarter 2025 financial results, highlighting positive topline data from the Phase 3 VERITAC-2 trial and strategic corporate updates.
Arvinas reported a net income of $82.9 million for the first quarter of 2025, a significant improvement from a net loss of $69.4 million in the same period last year, driven by a substantial increase in revenue to $188.8 million. The company also announced positive Phase 3 trial results for vepdegestrant and strategic reprioritization of its development plans, including workforce reductions to extend cash runway.
- Reported positive topline results from the Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings.
- Announced the re-prioritization of vepdegestrant development plan, removing two Phase 3 combination trials, to maximize patient benefit and shareholder value.
- Initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028.
- Presented first-in-human data for ARV-102, showing blood-brain barrier penetration and central and peripheral LRRK2 degradation, with good safety and tolerability.
Headline financials
Revenue & EPS history
Arvinas · Revenue · Quarterly
$189M
Revenue by segment
Arvinas · $30.3M total across 1 segment · Q3 2022
- Collaboration Revenue$30.3M+225.8%100.0%
Forward guidance
Arvinas expects its current cash, cash equivalents, and marketable securities to fund planned operating expenses and capital expenditure requirements into the second half of 2028. The company plans to present detailed VERITAC-2 results, share data with global regulatory authorities for potential filings, and continue clinical development for ARV-102 and ARV-393.
Tailwinds
- Cash runway extended into the second half of 2028 due to cost reductions.
- Detailed results from VERITAC-2 Phase 3 clinical trial to be presented at ASCO (2Q 2025).
- Plans to share VERITAC-2 data with global regulatory authorities to support regulatory filings (2Q 2025) and submit new drug application to the U.S. FDA (2H 2025).
- Addition of a combination cohort of vepdegestrant plus Pfizer's KAT6 inhibitor to Pfizer's ongoing Phase 1 trial.
- Initiation of the MAD cohort of the Phase 1 clinical trial in patients with Parkinson's disease (2H 2025) for ARV-102.
Headwinds
- Removal of two Phase 3 trials from the vepdegestrant development plan (first-line combination with atirmociclib and second-line combination with a CDK4/6 inhibitor).
- Workforce reduction of approximately one-third across the Company.
- Potential impact of workforce reduction on ability to retain skilled personnel and business reputation.
- Uncertainty regarding future vepdegestrant combination plans with Pfizer.
- Reliance on third parties for successful clinical development and commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-2.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-0.6%
Avg return
30 days after
30%
9 / 30 earnings
Positive
+11.8%
Q1 2019
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.4% | -10.2% | — | |
| Q4 2025 | +5.2% | +4.7% | -7.4% | |
| Q3 2025 | +0.5% | +17.3% | +34.1% | |
| Q1 2025 | -24.8% | -27.8% | -25.2% | |
| Q4 2024 | -6.8% | -3.5% | -54.9% | |
| Q3 2024 | -3.9% | -2.5% | -2.8% | |
| Q2 2024 | -1.0% | -7.0% | -6.3% | |
| Q1 2024 | +0.3% | -2.5% | -14.1% | |
| Q4 2023 | -5.8% | -3.1% | -15.4% | |
| Q3 2023 | -2.5% | -11.5% | +93.1% | |
| Q2 2023 | +2.1% | +6.8% | +12.8% | |
| Q1 2023 | +4.9% | +3.0% | -1.2% | |
| Q4 2022 | -7.0% | -10.8% | -23.0% | |
| Q3 2022 | -4.0% | +17.9% | -12.5% | |
| Q2 2022 | +3.8% | +4.5% | -19.3% | |
| Q1 2022 | -16.4% | -22.6% | -19.0% | |
| Q4 2021 | -2.6% | -4.4% | -5.4% | |
| Q3 2021 | +4.9% | +1.2% | -18.8% | |
| Q2 2021 | -4.3% | -8.9% | -13.4% | |
| Q1 2021 | -4.0% | -9.1% | -1.7% | |
| Q4 2020 | -1.0% | -8.0% | -15.6% | |
| Q3 2020 | -3.6% | +4.3% | +18.6% | |
| Q2 2020 | -5.0% | -11.1% | -23.0% | |
| Q1 2020 | -0.9% | -6.0% | -17.7% | |
| Q4 2019 | -3.2% | -1.8% | +14.2% | |
| Q3 2019 | +3.3% | +17.6% | +79.4% | |
| Q2 2019 | -4.6% | -0.2% | -1.5% | |
| Q1 2019 | +11.8% | +11.1% | +0.8% | |
| Q4 2018 | -3.0% | -6.9% | +42.9% | |
| Q3 2018 | -0.1% | +7.3% | -13.6% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro